|Bid||0.0000 x 4000|
|Ask||0.0000 x 21500|
|Day's range||1.9800 - 2.2200|
|52-week range||1.4700 - 17.4200|
|Beta (5Y monthly)||1.64|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Not long ago, Amyris and Gingko Bioworks were stock-market darlings, but the rout in tech stocks this year has been especially tough on these two. Shares of this synthetic biology start-up shot higher following its stock-market debut last year. The good times didn't last long, though, and now Gingko Bioworks stock is down more than 80% from its all-time high.
Amyris (AMRS) sees strong revenues in its consumer segment in Q1 driven by growth of its legacy brands and strong contribution from new brands.
This call is being webcast live on the events page of the investors' section of Amyris website at amyris.com. You may listen to a webcast replay of this call by going to the investors' section of Amyris website. With me on today's call is John Melo, president and chief executive officer.